Quit-smoking drug safe for patients with chronic lung conditions

Washington DC: A new research has found that drugs which helps smokers to quit smoking is safe for people with chronic lung conditions.

Experts have said that smokers with smoking-related diseases should be prescribed the drug to stop their illness from progressing.

Doctors have previously been reticent to give the drug to these patients because of reported links to heart disease and depression.

Researchers said that they found no evidence of such a link and that concerns are unwarranted.

Varenicline is the most effective medication to help smokers quit, but previous reports have suggested that users may be more likely to suffer a heart attack.

The drug, also known as Champix or Chantix, has also been linked to depression, self-harm and suicide.

A study of more than 14,000 people with chronic obstructive pulmonary disorder, or COPD, found that those using the drug were no more likely to suffer a heart attack than those using nicotine replacement therapies.

Treatment did not affect their risk of depression or self-harm either, researchers say.

COPD is a group of lung conditions that are usually associated with tobacco smoking, including emphysema and chronic bronchitis. The diseases are caused by damage to the lungs that results in severe breathing difficulties and a persistent cough.

The study was led by researchers from the Universities of Edinburgh and Dusseldorf and is published in Thorax.

Researcher Aziz Sheikh said: "Varenicline is a highly effective anti-smoking drug so it is reassuring that our findings have confirmed that it is safe for use in patients with COPD.

(With ANI inputs)